NKGen Biotech, Inc.
NKGN
$0.06
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.74% | -11.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.51% | -24.87% | |||
| Operating Income | 8.51% | 24.87% | |||
| Income Before Tax | 152.28% | -545.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 152.19% | -545.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 152.19% | -545.80% | |||
| EBIT | 8.51% | 24.87% | |||
| EBITDA | 9.99% | 25.97% | |||
| EPS Basic | 145.40% | -424.81% | |||
| Normalized Basic EPS | 192.55% | -2.55% | |||
| EPS Diluted | 94.57% | -582.96% | |||
| Normalized Diluted EPS | 141.46% | -45.48% | |||
| Average Basic Shares Outstanding | 14.95% | 37.24% | |||
| Average Diluted Shares Outstanding | 156.74% | -3.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||